This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Watch the video below to find out how our 30-year commitment to rare disease1 means we always lead with science, and put patients, their families, and the community at the centre of everything we do. 

Why Nexviadyme was developed

From the challenges of cell delivery, to optimising targeting,2,4 explore why Sanofi developed Nexviadyme®.

How Nexviadyme®  was designed

Watch how we used preclinical mice models of Pompe to design Nexviadyme®, and improve maintenance of muscle strength compared to Myozyme®.3,5

1/2

Why Nexviadyme was developed

From the challenges of cell delivery, to optimising targeting,2,4 explore why Sanofi developed Nexviadyme®.

How Nexviadyme®  was designed

Watch how we used preclinical mice models of Pompe to design Nexviadyme®, and improve maintenance of muscle strength compared to Myozyme®.3,5

References
  1. Mistry, P.K. et al. Rare lysosomal disease registries: lessons learned over three decades of real-world evidence. Orphanet Journal of Rare Diseases. 2022;17:362.
  2. Chien YH, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. Journal of Pediatrics. 2015 Apr;166(4):985-91.e1-2.

  3. Sanofi. Nexviadyme (avalglucosidase alfa). Summary of Product Characteristics. 2023. Available at: https://www.medicines.org.uk/emc/product/14562/smpc#gref.
  4. Zhu Y, et al. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. The Biochemical Journal. 2005 Aug 1;389(Pt 3):619-628.

  5. Zhu Y, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Molecular Therapy. 2009 Jun;17(6):954-63.

MAT-XU-2302328 (v2.0) Date of preparation: November 2023